Abstract:Xue Fang Li, 1 Shi Rong Liu, 2 Jin Jin Li, 1 Ning Liu, 2 Hui Min Li, 3 An Ning Ge, 4 Liang Liang Wang, 5 Xie Min Dong, 1 Hui Wang, 1 Ju Liu, 1 Lin Zhang, 1 Hao Dong Zhang, 1 Wei Gou 1 1 Department of Metabolic Liver Disease, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China; 2 Infectious Diseases department, People's Hospital of Qu fu City, Qufu City, Shandong Province, People's Republic of China; 3 Infection Department, Jiaozhou Branch of Shanghai East Hospital Tongji University, Qingdao City, Shandong Province, People's Republic of China; 4 Department of Infectious Diseases, People's Hospital of Rizhao City, Rizhao City, Shandong Province, People's Republic of China; 5 Medical Intervention Department, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China Correspondence: Wei Gou, Department of Metabolic Liver Disease, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China, Tel +86-15666687727, Fax +86-532-81636699, Email Objective: To investigate the risk factors for the development of portal hypertension in patients with decompensated cirrhosis and analyze their prognosis. Methods: Patients with decompensated cirrhosis who were admitted to our hospital and Qu fu People's Hospital from June 2022 to June 2023 were included in this study. Among them, there were 45 male and 15 female patients, with a median age of 56 (range: 35– 77) years. A comparative analysis was performed between Group A (hepatic venous pressure gradient, HVPG < 16 mmHg) and Group B (HVPG ≥ 16 mmHg) patients, along with various clinical outcomes. Multivariate analysis was conducted to explore the risk factors influencing the occurrence of portal hypertension and adverse prognosis in patients with cirrhosis. Results: In Group A patients with portal hypertension, we observed lower levels of aspartate aminotransferase, laminin, serum hyaluronic acid, type III procollagen N-terminal peptide, total bile acids, and cholylglycine acid compared to Group B. On the other hand, levels of alanine aminotransferase, white blood cells, and serum albumin were higher in Group A than in Group B. These differences between the groups were statistically significant (P < 0.05). Multivariate analysis of the aforementioned risk factors indicated that low white blood cell count, high cholylglycine acid levels, and high serum hyaluronic acid levels were identified as independent risk factors for the occurrence of difficult-to-control complications in decompensated portal hypertension among patients with liver cirrhosis (P < 0.05). Conclusion: Liver cirrhosis patients with portal hypertension and multiple risk factors like low white blood cell count and high liver transaminase levels should be cautious regarding the progression of portal hypertension when combined with splenomegaly, liver fibrosis, and bile stasis, as it often indicates a poor prognosis. Keywords: portal hypertension, white blood cells, glycine cholate, serum hyaluronic acid According to statistics, the number of patients with chronic liver diseases in China, including chronic hepatitis, fatty liver, and cirrhosis, may exceed 447 million in 2020. Cirrhosis, as a major cause of morbidity and mortality in hepatic diseases, affects over 120 million people worldwide. 1 Decompensated cirrhosis serves as a turning point in the prognosis, primarily manifested by complications such as ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or variceal bleeding. Accurate staging of decompensated cirrhosis can significantly reduce the risk of mortality. 2 Measurement of HVPG is considered the gold standard for assessing portal hypertension, with HVPG ≥ 16 mm Hg indicating a higher likelihood of refractory complications. 3 Although there have been numerous studies on the risk factors for decompensated cirrhosis in patients with liver cirrhosis, there is a paucity of research focused on the risk factors for decompensated cirrhosis with concomitant portal hypertension. In this study, we conducted a retrospective analysis of clinical data from 60 patients with decompensated cirrhosis from our hospital and People's Hospital of Qu fu City. By employing univariate and multivariate logistic regression analysis, we aimed to identify the risk factors for rebleeding in these patients. In this retrospective analysis, we selected patient records meeting our study criteria from the inpatient electronic case systems at Qingdao Sixth People's Hospital and Qu fu Municipal Hospital. All particip -Abstract Truncated-

[Clinical Features and Prognosis of Decompensated Hepatitis C Virus Related Cirrhosis].

Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension

Multivariate analysis of hepatic encephalopathy occurrence in patients with liver failure

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy

The Clinical Course of Cirrhosis Patients Hospitalized for Acute Hepatic Deterioration: A Prospective Bicentric Study.

[An Analysis of Clinical Characteristics and Risk Factors of Cirrhosis-Related Hepatocellular Carcinomas in Patients with Hepatitis C Virus Infection].

Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding

Hepatitis E virus superinfection impairs long-term outcome in hospitalized patients with hepatitis B virus-related decompensated liver cirrhosis

Recompensation of complications in patients with hepatitis B virus-related decompensated cirrhosis treated with entecavir antiviral therapy

Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites

The development of cirrhosis in Chinese patients with chronic hepatitis B

Effect of antiviral therapy on prognosis of patients with decompensated cirrhosis

Approach to the patient with chronic hepatitis B and decompensated cirrhosis

Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria

Prognosis Prediction Performs Better in Patients with Non-Cirrhosis Hepatitis B Virus-Related Acute-on-chronic Liver Failure Than Those with Cirrhosis.

Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis

Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis

Recompensation of Chronic Hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: Prospective Cohort study from an HCV elimination program

Antiviral Therapy for Hepatitis B Virus‐related Decompensated Cirrhosis

Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients.